Alloy Therapeutics
VC Fund
Lexington, United States
Alloy Therapeutics is a VC fund in Lexington focused on Biotechnology and Therapeutics. Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 70%
Last updated:
For AI agents: llms.txt
Industries Alloy Therapeutics invests in
Stages Alloy Therapeutics invests in
Countries Alloy Therapeutics invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joshua Brandt
|
|||
Richard Shimkets
|
|||
Errik Anderson
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 4 (40%)
- Therapeutics 2 (20%)
- Health Care 1 (10%)
- Life Science 1 (10%)
- Service Industry 1 (10%)
Stage
- Series A 3 (30%)
- Seed 2 (20%)
- Funding Round 2 (20%)
- Corporate Round 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joshua Brandt
Associate General Counsel
|
Associate General Counsel | Total investments: 0 | Find email | |
|
Richard Shimkets
SVP Genetics and New Technologies
|
SVP Genetics and New Technologies | Total investments: 0 | Find email | |
|
Errik Anderson
Founder, Chairman and CEO
|
Founder, Chairman and CEO | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wheeler Bio
|
Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $35M / Series A / Mar 20, 2025 | |
|
Wheeler Bio
|
Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $31M / Series A / Oct 04, 2022 | |
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Jun 02, 2022 | |
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Series A / Jun 02, 2022 | |
Tegmine Therapeutics
|
Tegmine Therapeutics is private, seed-stage biotech that develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications. | Corporate Round / Apr 06, 2022 | |
Mytide Therapeutics
|
Mytide is committed to providing peptides to serve a diverse array of applications. They intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. They provide initial partners access totheir cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display. | $7M / Series A / Mar 08, 2022 | |
|
Wheeler Bio
|
Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $14M / Seed / Jan 04, 2022 | |
|
Wheeler Bio
|
Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | Jul 21, 2021 | |
|
Wheeler Bio
|
Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | Seed / Jul 21, 2021 | |
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | Seed / Jul 12, 2021 |
Co-Investors
Echo Investment Capital
5 deals together
Charles River Laboratories International
3 deals together
Atum
2 deals together
Dynamk Capital
2 deals together
Ampersand Capital Partners
1 deal together
Floating Point Group
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alloy Therapeutics invest in?
Alloy Therapeutics invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alloy Therapeutics?
Public channels for Alloy Therapeutics include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alloy Therapeutics?
The team at Alloy Therapeutics includes Joshua Brandt (Associate General Counsel), Richard Shimkets (SVP Genetics and New Technologies) and Errik Anderson (Founder, Chairman and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
